Why updated TRUST-I and TRUST-II results make IBTROZI a top contender in targeted lung cancer therapy

Nuvation Bio Inc. (NYSE: NUVB) has released comprehensive updated findings from its pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). Presented at the 2025 World Conference on Lung Cancer in Barcelona, the data reaffirm the drug’s long-term efficacy, central nervous system (CNS) activity, and tolerable safety profile—cementing its position as a leading option in this genetically defined NSCLC subtype.

IBTROZI was approved by the U.S. Food and Drug Administration on June 11, 2025, for the treatment of locally advanced or metastatic ROS1-positive NSCLC, both in tyrosine kinase inhibitor (TKI)-naïve and TKI-pretreated patients. This update, building on that regulatory milestone, comes as Nuvation Bio rolls out the drug commercially across a diverse base of prescribers, including over 50 academic and community cancer centers. Institutional investors and analysts have responded positively to the emerging clinical and commercial momentum, citing IBTROZI’s durability, brain penetration, and safety profile as key differentiators in the highly competitive ROS1-targeted therapy landscape.

What do the new TRUST-I and TRUST-II results reveal about IBTROZI’s progression-free survival and intracranial activity?

The TRUST program’s new long-term results underscore IBTROZI’s potential as a durable and CNS-active treatment option. In the global TRUST-II trial, treatment-naïve patients (n=54) achieved an 85.2% confirmed objective response rate (cORR), with median progression-free survival (PFS) not yet reached at a median follow-up of 20.5 months. The longest PFS recorded was 31.6 months and ongoing. A full 74% of patients experienced a DOR of at least 12 months, and 68% sustained responses beyond 18 months. Among patients with brain metastases, the intracranial response rate was 66.7%.

Meanwhile, the China-based TRUST-I study showed a 90.3% cORR in TKI-naïve patients (n=103), with a median PFS of 44.6 months and the longest DOR extending past 46.9 months. For patients with brain metastases, the intracranial response rate stood at 87.5%, reflecting substantial CNS activity.

In previously treated patient groups, TRUST-II showed a 61.7% cORR, a median PFS of 11.8 months, and a median DOR of 19.4 months. TRUST-I recorded a 51.5% cORR in pretreated patients (n=66), with a median PFS of 7.6 months and DOR of 13.2 months. Together, these findings highlight IBTROZI’s consistency across lines of therapy and reinforce its suitability for both frontline and salvage settings.

How does IBTROZI’s safety profile support its use in long-term NSCLC treatment?

IBTROZI’s safety profile, as observed across 337 patients in the pooled TRUST-I and TRUST-II dataset, was favorable and consistent with targeted therapies in this class. The most common treatment-emergent adverse events (TEAEs)—including diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), and fatigue (20%)—were mostly Grade 1 or 2 in severity and resolved rapidly within a median timeframe of 1 to 3 days. Importantly, these TEAEs did not lead to any treatment discontinuations.

Liver enzyme elevations occurred in approximately 76% of patients. Grade 3 or 4 AST and ALT increases were seen in 10% and 13% of patients, respectively. Despite the frequency of hepatic AEs, only one discontinuation was recorded due to hepatotoxicity, and these effects were typically managed through dose interruption or reduction.

Other noted risks included QTc prolongation (13% experienced >60ms increase), interstitial lung disease (2.3%, with one fatal case), hyperuricemia (14%, with 0.3% experiencing Grade ≥3), and myalgia with CPK elevation. Skeletal fractures occurred in 3.4% of patients, mostly in the context of falls or predisposing conditions.

These data support a tolerable safety profile that permits sustained therapy—critical in a disease setting where long-term disease control is a key objective. Clinicians are advised to monitor liver function and cardiac intervals, and to counsel patients on potential photosensitivity and embryo-fetal risks.

How is IBTROZI performing commercially following its U.S. launch in June 2025?

Since gaining FDA approval, Nuvation Bio has made rapid progress in commercializing IBTROZI. As of July 31, 2025—just seven weeks post-launch—over 70 patients had been started on the drug across more than 50 prescribers, spanning both academic hospitals and private practice oncology networks.

The company generated $1.2 million in revenue from IBTROZI during Q2 2025, primarily from stocking and initial trial programs. While early, this commercial uptake is being seen as an encouraging signal by analysts tracking targeted oncology launches. IBTROZI has already been included in the National Comprehensive Cancer Network (NCCN) guidelines as a recommended treatment for ROS1-positive NSCLC, with or without brain metastases.

Priced at $29,488 per month in the United States, the drug is being positioned as a high-value therapy in a precision-medicine niche. Forecasts published by Reuters estimate peak U.S. sales of up to $640 million by 2034, driven by IBTROZI’s CNS penetration and strong first-line activity. These projections are notably competitive when compared to existing ROS1 inhibitors like entrectinib and crizotinib.

What is next for the TRUST program and IBTROZI’s global development?

Nuvation Bio is continuing to advance IBTROZI’s clinical development globally. The TRUST-III study, a Phase 3 randomized trial comparing taletrectinib to crizotinib, is currently enrolling. If successful, TRUST-III could reinforce IBTROZI’s positioning as a superior frontline treatment option.

Further data readouts from both TRUST-I and TRUST-II are expected later this year at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. These will include subgroup analyses, pharmacokinetics, and additional CNS response metrics.

The company is also preparing regulatory submissions in Europe, China, and other priority markets. Outside IBTROZI, Nuvation Bio continues to invest in its broader oncology pipeline, including safusidenib (a brain-penetrant IDH1 inhibitor), NUV-1511 (a drug-drug conjugate designed for targeted tumor delivery), and NUV-868 (a selective BD2 BET inhibitor).

Founder and CEO Dr. David Hung, whose previous success with Medivation’s Xtandi culminated in a $14 billion Pfizer buyout, described IBTROZI as a “paradigm-changing therapy” in ROS1-positive NSCLC. Experts presenting at WCLC echoed this assessment, particularly praising its durable CNS control and differentiated activity in pretreated populations.

How are institutional investors viewing Nuvation Bio following the IBTROZI update?

While shares of Nuvation Bio (NYSE: NUVB) experienced some volatility after the June approval, market sentiment has remained largely constructive. The stock is currently trading in the $2.00–$2.20 range as of early September 2025, with a market capitalization around $450 million.

Analysts are closely watching the progression of TRUST-III and global regulatory filings as key catalysts for further upside. While some institutional investors have flagged IBTROZI’s niche patient population and need for CNS monitoring as potential hurdles, many view the drug’s CNS activity, tolerability, and front-to-back-line utility as compelling advantages over legacy TKIs.

With a rapidly expanding clinical dataset, favorable guideline positioning, and growing commercial traction, IBTROZI is increasingly seen as a cornerstone in Nuvation Bio’s emerging precision oncology franchise.